AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access
Executive Summary
In addition to endometriosis, Orilissa (elagolix), developed by Neurocrine and licensed to Abbvie, is in Phase III for treating heavy bleeding associated with uterine fibroids.
You may also be interested in...
Myovant/Pfizer Launch Myfembree With An Emphasis On Building Uterine Fibroid Awareness
Myovant CEO David Marek talked to Scrip about why the companies believe patients and physicians will choose Myfembree over AbbVie's Oriahnn.
Yselty For Uterine Fibroids Edges Closer To Being Obseva’s First Commercial Product
Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but the GnRH agonist is behind two rival drugs: AbbVie's elagolix and Myovant's relugolix.
Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids
Relugolix meets primary and six key secondary endpoints in first Phase III UF study. Magnitude of benefit for primary endpoint does not equal AbbVie’s elagolix, but Myovant thinks it will offer safety, tolerability and convenience advantages.